Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low-dose computed tomography Clear all

Conditions: Lung Cancer
Interventions: Low-dose CT scan; Device
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 125
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Anaheim, California + 105 more

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: Breathe BioMedical Inc; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: High Risk of Developing Lung Cancer
Interventions: CT scan & Early CDT Lung test, CT scan & Early CDT Lung test; Radiation · Other
Lead sponsor: National Jewish Health; Other
Eligibility: 50 Years to 75 Years
Enrollment: 1,361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Lung Cancer
Interventions: Centralized Screening Unit Implementation; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 50 Years to 77 Years
Enrollment: 9,460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Smoking Cessation
Interventions: Questionnaires, Low Dose Computed Tomography Scan, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, Carbon Monoxide (CO) Level Test; Behavioral · Procedure · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HNSCC
Interventions: Cesium-131, Pembrolizumab; Device · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Carcinoma, Sarcoma, Myeloma, Lymphoma, Melanoma
Interventions: [18F]-SKI-249380, PET/CT scan, Blood draws; Radiation · Procedure · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Illness
Interventions: Low Dose CT scan; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease
Interventions: low-dose stress MPI SPECT; Other
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer Screening, Military Service-related Environmental and Occupational Exposures, Cancer Survivor, Family History of Lung Cancer, COPD, Burn Pit Exposure, Agent Orange Exposure, Radiation Exposure, Asbestos Exposure, Lung Neoplasm
Interventions: Low-dose computed tomography; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 80 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Louisville, Kentucky + 4 more

Conditions: Early Detection of Cancer, Lung Neoplasms
Interventions: EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening; Other
Lead sponsor: University of Utah; Other
Eligibility: 55 Years to 80 Years
Enrollment: 1,855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Kidney Stones
Interventions: Ultra low dose CT scan, Regular CT or Low Dose CT scan, No imaging; Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Interventions: MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492; Procedure · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more

Conditions: Breast Screening
Interventions: Contrast-Enhanced Spectral Mammography; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Computed Tomography, Nasopharyngeal Laryngoscopy, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Chicago, Illinois • Warrenville, Illinois

Conditions: Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent, Endometroid Ovarian Carcinoma, Clear Cell Ovarian Carcinoma
Interventions: Cytokine-Induced Memory-like Natural Killer Cells, Interleukin 2; Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 50 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Lung Injury, Early Pulmonary Neutrophilic Inflammation
Interventions: PET-CT scan; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions: Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest; Drug · Device · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more

Conditions: Coronary Disease
Interventions: Cannon Aquilion ONE CT system; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
Interventions: triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography; Drug · Radiation · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions: Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET); Procedure · Drug
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions: [18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography; Diagnostic Test · Other · Device
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Screening for High Frequency Malignant Disease

Analysis of Volatile Chemicals in Lung Cancer Screen-Eligible Subjects Using Infrared Spectroscopy

Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Centralized Screening Unit (CSU) at Montefiore-Einstein

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Comprehensive Lung Health

Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography

Personalizing Veterans' Lung Cancer Screening and Diagnosis

Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening

Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis

Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Surveillance For New Lung Primaries

PET Imaging in Patients at Risk for Acute Lung Injury

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Evaluating New Radiation Techniques for Cardiovascular Imaging

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

FDG-PET in Advanced Melanoma